Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.45 |
| ▸ | CCND1 | P24385 | 17/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 16/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 14/20 | 0.45 |
| ▸ | CDK4 | P11802 | 10/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.45 |
| ▸ | CDK9 | P50750 | 7/20 | 0.45 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30804799 | 0.94 | CDK2 (0.46) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27174709 | 0.94 | CDK2 (0.46) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27062123 | 0.88 | CDK2 (0.49) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27061974 | 0.87 | CDK2 (0.48) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27033611 | 0.85 | CDK2 (0.48) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL30726224 | 0.85 | CDK2 (0.48) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27062986 | 0.85 | CDK2 (0.48) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL30804788 | 0.82 | CDK2 (0.49) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27061913 | 0.82 | CDK2 (0.49) | CDK2CCND1CCNE1CDK6CDK4 | |
| SCHEMBL27061905 | 0.81 | CDK2 (0.47) | CDK2CCND1CCNE1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDK3, CDK1 | CDK2 5/4885CCND1 91/4885CCNE1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.